Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma

NCT03495921 is registered in ClinicalTrials.gov with Gradalis, Inc. as lead sponsor.

NCT NCT03495921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03495921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma
Lead sponsor
Gradalis, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
August 21, 2018
Completion date
January 20, 2022
Enrollment
32 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

ewing family of tumors, ewing sarcoma, ewing's sarcoma metastatic, ewing's tumor metastatic, ewing's tumor recurrent, neoplasms, neoplasms by histologic type, neoplasms, bone tissue, neoplasms, connective and soft tissue, neoplasms, connective tissue, rare diseases, sarcoma, sarcoma, ewing